Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.
J Nucl Med
; 58(7): 1054-1057, 2017 07.
Article
de En
| MEDLINE
| ID: mdl-28153957
ABSTRACT
Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases. Methods:
Forty patients with metastatic NET and unknown primary site underwent 68Ga-DOTATOC PET/CT in a single-site prospective study. The 68Ga-DOTATOC PET/CT was considered true-positive if the positive primary site was confirmed by histology or follow-up imaging. The scan was considered false-positive if no primary lesion was found corresponding to the 68Ga-DOTATOC-positive site. All negative scans for primary tumor were considered false-negative. A scan was classified unconfirmed if 68Ga-DOTATOC PET/CT suggested a primary, however, no histology was obtained and imaging follow-up was not confirmatory.Results:
The true-positive, false-positive, false-negative, and unconfirmed rates for unknown primary tumor were 38%, 7%, 50%, and 5%, respectively.Conclusion:
68Ga-DOTATOC PET/CT is an effective modality in the localization of unknown primary in patients with metastatic NET.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Composés organométalliques
/
Métastases d'origine inconnue
/
Octréotide
/
Tumeurs neuroendocrines
/
Tomographie par émission de positons couplée à la tomodensitométrie
Type d'étude:
Diagnostic_studies
/
Observational_studies
Limites:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
J Nucl Med
Année:
2017
Type de document:
Article